Can You Take Ozempic While Breastfeeding? What the Evidence Shows

The answer depends on the exact medicine and formulation, why you need treatment, and your infant's circumstances. Small milk-transfer studies of injectable medicines do not establish safety for every breastfeeding family. Oral semaglutide products have a different absorption ingredient and their labels advise against breastfeeding during treatment⁸⁶.

Ozempic and Wegovy: the shot and the pill are labeled differently

This is the detail almost every roundup on this topic misses: Wegovy's own FDA label does not treat "semaglutide and breastfeeding" as one question. For the oral tablet, a clinical lactation study found SNAC — the absorption-enhancing ingredient that lets semaglutide survive being swallowed — present in human milk, and because infants may clear SNAC more slowly than adults, the label states plainly that breastfeeding is not recommended during treatment with the tablet. For the subcutaneous injection — the form most women on this medication actually use, and the one that contains no SNAC — the label instead says there are no data on its presence in human milk or its effects on a breastfed infant, and leaves the decision to weighing the drug's benefit against the infant's needs with a clinician. Those are two different regulatory postures for two different products carrying the same drug name, and conflating them is the single most common mistake in what gets written about this topic.

What each GLP-1 label says about breastfeeding

The tirzepatide finding comes from a single-dose study in 11 breastfeeding women. Tirzepatide was undetectable in 164 of 171 milk samples, and the total found over 28 days was less than 0.02% of the mother's dose⁹. That is reassuring but narrow: one dose, a small group, and no data on the babies themselves. Foundayo is a newer daily pill; it was found in the milk of lactating rats, and its label advises against it while nursing¹⁰. Our Foundayo vs Wegovy pill guide compares the two pills.

What the newest human data actually found

A 2024 study measured semaglutide in milk samples from eight women using the injection, collected before and at twelve and twenty-four hours after administration. Semaglutide was not detected within the assay's limits. The authors calculated a conservative exposure estimate using the detection limit rather than a measured infant dose¹.

This is evidence about transfer into sampled milk, not a randomized trial of infant safety. A small modeled relative infant dose does not answer every question about long-term development, milk production or maternal nutrient intake. It should not be turned into a blanket claim that any semaglutide dose is safe throughout breastfeeding.

The current Zepbound label adds a separate single-dose tirzepatide milk study and explicitly notes the absence of data on effects in breastfed infants or milk production⁹. Repeated weekly dosing and the health of an individual baby need their own assessment. A reassuring transfer result and a complete lactation-safety evidence base are different things.

Questions about the baby and feeding matter too

Bring the baby's age, any prematurity or medical problems, the amount of breastfeeding and any concerns about growth or feeding to the discussion. The clinician and pediatric team should explain how those circumstances affect the decision, rather than relying on the medicine name alone.

Ask what will be monitored if treatment is used, and whom to contact if feeding or maternal intake changes. A plan should account for the mother's medical need as well as infant nutrition. Neither abrupt weaning nor restarting an old prescription is an automatic response to reading a small study.

The postpartum weight question underneath this

Part of why this comes up so often is that postpartum weight retention is a real and common experience, and pregnancy-related weight gain that doesn't resolve on its own carries downstream metabolic risk⁵. A 2025 position statement on obesity across the female reproductive life course frames breastfeeding and postpartum weight management as connected rather than competing goals — the priority during active breastfeeding is protecting milk supply and infant nutrition, with more aggressive weight-loss tools generally deferred until weaning unless a clinician judges otherwise for a specific patient⁵. If you started a GLP-1 before pregnancy or fertility treatment, that same conversation about timing applies again on the way back out.

What this means in practice

Identify the exact formulation before discussing a restart, including whether it is a branded injection, tablet or compounded preparation. Ask the prescriber and pediatric or lactation team to review the purpose of treatment, evidence limits, feeding circumstances and follow-up. The oral-product warning should not be transferred to every injection, and low milk transfer should not be described as proof of no infant risk.

If treatment stopped during pregnancy, do not assume the old dose remains appropriate after delivery. Our missed-dose and restart guide explains why a long interruption is different from one late dose. If the interruption involves another procedure, the surgery and endoscopy guide helps coordinate the prescription with that team's instructions.

For the other side effects women weigh on these medicines, see our hub on GLP-1 side effects in women.